Acute Graft-vs-Host-Disease (aGvHD)
- US Prevalence is estimated at approximately 5,000 cases and occurs in up to 50% of allogeneic stem cell transplant recipients(1)
- Onset of aGvHD typically occurs within 3 months of transplant
- Symptoms occur in the skin (rash), GI tract (vomiting, diarrhea) and liver (jaundice)
(1) https://doi.org/10.1186/1750-1172-2-35
Chronic Graft-vs-Host-Disease (cGvHD)
- US Prevalence is estimated at approximately 14,000 cases and occurs in up to 40% of recipients(2)
- In addition to symptoms in the skin, GI tract and liver, cGvHD may also manifest itself in the lungs, mucosal surfaces (eyes, mouth, GU tract), muscle and joints (connective tissue)
(2) https://pubmed.ncbi.nlm.nih.gov/34158154/
Vitiligo
- Vitiligo is an autoimmune disease of the skin mediated primarily by NK and CD8+ T cells that attack melanocytes leading to patchy depigmentation of the skin
- It is estimated that vitiligo affects 2 million people in the U.S (NIH)
- The global vitiligo treatment market size was estimated at $1.2 billion in 2018 and is projected to reach $1.9 billion by 2026 (Fortune Business Insights)
Alopecia Areata (AA)
- AA is an autoimmune disease in which immune cells attack and damage hair follicles and is mediated primarily by CD8+ T cells and NK cells
- The global alopecia treatment market was valued at $2.7 billion in 2018, and is projected to reach $3.9 billion by 2026, registering a CAGR of 4.6% from 2019 to 2026 (Allied Mkt Research)